https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Olema_Pharmaceuticals%2C_Inc.Olema Pharmaceuticals, Inc. - Revizia istoricului2026-04-06T12:37:46ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Olema_Pharmaceuticals,_Inc.&diff=433871&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Olema Pharmaceuticals, Inc. listata cu simbolul US.OLMA ==Descriere companie== Olema Pharmaceuticals, Inc. (https://olema.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN), and a selective ER...2024-09-18T18:18:26Z<p>Pagină nouă: Pagina dedicata companiei Olema Pharmaceuticals, Inc. listata cu simbolul US.OLMA ==Descriere companie== Olema Pharmaceuticals, Inc. (https://olema.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN), and a selective ER...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Olema Pharmaceuticals, Inc. listata cu simbolul US.OLMA<br />
<br />
==Descriere companie==<br />
Olema Pharmaceuticals, Inc. (https://olema.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN), and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed by based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumour shrinkage in several xenograft models, including a breast cancer brain metastasis model.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.OLMA" /><br />
<br />
==Ultimele stiri despre Olema Pharmaceuticals, Inc. (US.OLMA)==<br />
<dynamicpagelist><br />
category=US.OLMA<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.OLMA]][[Categorie:Stiri despre companii]]</div>Admin